Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01522820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01522820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2012
Completion date
July 31, 2016
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, estrogen receptor negative, estrogen receptor positive, glioblastoma, hormone-resistant prostate cancer, metastatic prostate carcinoma, metastatic renal cell cancer, recurrent adult brain neoplasm, recurrent bladder carcinoma, recurrent breast carcinoma, recurrent colorectal carcinoma, recurrent esophageal carcinoma, recurrent gastric carcinoma, recurrent hepatocellular carcinoma, recurrent lung carcinoma, recurrent melanoma, recurrent ovarian carcinoma, recurrent prostate carcinoma, recurrent renal cell carcinoma, recurrent uterine corpus carcinoma, resectable hepatocellular carcinoma, sarcoma, stage ia breast cancer, stage ia ovarian cancer, stage ia uterine corpus cancer, stage ib breast cancer, stage ib ovarian cancer, stage ib uterine corpus cancer, stage ic ovarian cancer, stage ii uterine corpus cancer, stage iia breast cancer, stage iia lung carcinoma, stage iia ovarian cancer, stage iib breast cancer, stage iib esophageal cancer, stage iib lung carcinoma, stage iib ovarian cancer, stage iib skin melanoma, stage iic ovarian cancer, stage iic skin melanoma, stage iiia breast cancer, stage iiia esophageal cancer, stage iiia lung carcinoma, stage iiia ovarian cancer, stage iiia skin melanoma, stage iiia uterine corpus cancer, stage iiib breast cancer, stage iiib esophageal cancer, stage iiib ovarian cancer, stage iiib skin melanoma, stage iiib uterine corpus cancer, stage iiic breast cancer, stage iiic esophageal cancer, stage iiic ovarian cancer, stage iiic skin melanoma, stage iiic uterine corpus cancer, stage iv bladder urothelial carcinoma, stage iv esophageal cancer, stage iv ovarian cancer, stage iv prostate cancer, stage iv skin melanoma, stage iva uterine corpus cancer, stage ivb uterine corpus cancer